- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05794113
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform
Comparing the Use of a Mobile App for Surveillance of Adverse Events Following Influenza Immunization to a Web-Based Platform: a Randomized Controlled Trial
Methods Study Procedures A two-centred randomized control trial (RCT) was conducted to evaluate the use of safety reporting via a mobile app compared to safety reporting via web-based CANVAS notifications amongst individuals receiving the influenza vaccine from October 6 to November 29, 2020 during the seasonal influenza vaccine campaign in Ottawa and Vancouver, Canada.
Individuals were recruited at the time of receiving their influenza vaccine. Eligibility criteria included the ability to speak English or French, having an active email address and telephone number, and being immunized with the seasonal influenza vaccine.
Randomization After study enrollment, participants were randomized to receive the online safety survey either through the mobile app or emailed a link to the online survey using a four-block randomization design.
Web-based notification arm All participants randomized to the web-based notification arm received the following web-based CANVAS notifications. Briefly, participants received an email notifying them of their registration in the study. Eight days following their influenza vaccine, participants received an email with the survey link asking them to complete their online influenza vaccine safety survey. Participants received a reminder email on day 11 if they did not complete their survey. Further details on CANVAS surveillance and description of the questionnaire can be found here.
Mobile app arm Participants randomized to the mobile app arm, received an email asking them to download the app and activate their account. Users who did not activate their account after 48 hours received a reminder email. Participants who activated their accounts, could spontaneously report an adverse event through the app, and were also notified of the day 8 survey through the app.
Eight days following their vaccination mobile app participants who activated their account received a push notification on their phone to complete their survey. A reminder push notice was sent out on day 11 to participants that had not yet competed the day 8 survey. On November 16, 2020 (mid-way through the recruitment period), additional email reminders in the mobile app arm were implemented on days 2, 4 and 6 to remind participants to register for the app. All participants received a day 8 email directing them to use their CANImmunize account to complete their influenza vaccine survey. Access to the survey link also was available in the email reminder.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Ottawa Hospital Research Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Speak English or French,
- Have an active email address and telephone • Immunized with the seasonal influenza vaccine
- Parents of children are eligible to participate after the first or second dose of vaccine
Exclusion Criteria:
- Those who do not meet the inclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Web-based notification arm
All participants randomized to the web-based notification arm received the following web-based CANVAS notifications [4,5].
Briefly, participants received an email notifying them of their registration in the study.
Eight days following their influenza vaccine, participants received an email with the survey link asking them to complete their online influenza vaccine safety survey.
Participants received a reminder email on day 11 if they did not complete their survey.
|
Using a web-based version of a survey
|
Experimental: Mobile app arm
Participants randomized to the mobile app arm, received an email asking them to download the app and activate their account.
Users who did not activate their account after 48 hours received a reminder email.
Participants who activated their accounts, could spontaneously report an adverse event through the app, and were also notified of the day 8 survey through the app.
|
Using a mobile app
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Useability
Time Frame: through study completion - average of 4 months
|
Following completion of the safety survey, all participants were sent a separate link by email to complete a user experience survey.
Participants were asked about their history of participating in the flu vaccine safety survey and whether they previously used the CANImmunize app.
Using a Likert scale, participants were asked questions on (i) perceived ease of use, (ii) perceived usefulness, (iii) their attitudes and intention of use towards the platform and (iv) questions pertaining to vaccine confidence and safety.
|
through study completion - average of 4 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne McCarthy, Ottawa Hospital Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- #20200591-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mobile Apps
-
University Hospital, BrestUnknownPhysical Activity | Pregnant | Mobile Health AppsFrance
-
VA Office of Research and DevelopmentDurham VA Medical Center; US Department of Veterans Affairs Center for Healthcare...CompletedIntroduction of Teledermatology Mobile AppsUnited States
-
University of IowaCompletedCardiovascular Diseases | Personal Health Records | Pharmaceutical Care | Mobile AppsUnited States
-
Chang Gung Memorial HospitalRecruitingQuality of Life | Mobile Apps | OstomyTaiwan
-
University Hospital, BrestUnknownBreast Cancer | Physical Activity | Mobile Health AppsFrance
-
University MariborNot yet recruitingDiabetes Mellitus, Type 2 | Type 2 Diabetes | Mobile Apps | Health Behavior | Disease, Chronic | Mobile Phone Use | Self-Care
-
University Grenoble AlpsCompletedMobile Applications | Mobile HealthFrance
-
Agri Ibrahim Cecen UniversityAtaturk UniversityNot yet recruiting
-
Universitaire Ziekenhuizen KU LeuvenEnrolling by invitationMobile ApplicationsBelgium
-
University of California, San FranciscoCompleted
Clinical Trials on Web based notification
-
Clínica BazterricaWithdrawn
-
University of SouthamptonCompletedType 2 Diabetes
-
Arizona State UniversityUniversity of Colorado, Denver; University of New MexicoUnknownChildhood Obesity | Childhood OverweightUnited States
-
NYU Langone HealthStanford University; Shaare Zedek Medical CenterCompletedAnxiety Disorders | Major Depression | Post Traumatic Stress DisorderIsrael
-
Seattle Children's HospitalCompletedChronic Pain | Headache | Central SensitisationUnited States
-
Henry Ford Health SystemNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Northwestern UniversityWithdrawnIndividuals at Risk for DepressionUnited States
-
University of North Carolina, Chapel HillRTI InternationalCompletedObesity | Overweight
-
Georgetown UniversityAlbert Einstein College of Medicine; University of MichiganCompletedTobacco Cessation | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco Dependence | Virus, Human Immunodeficiency | Tobacco-Use DisorderUnited States
-
Taipei Medical UniversityRecruitingInfertility | Heart Rate Variability | BiofeedbackTaiwan